https://decoytx.com/decoy-therapeutics-expands-intellectual-property-portfolio-covering-designable-multi-antivirals-and-the-imp%c2%b3act-platform/2026-08-31T14:39:02+00:00https://decoytx.com/decoy-therapeutics-announces-breakthrough-in-vitro-activity-against-ebola-zaire-expanding-d-mav-platform-into-high-consequence-global-health-threats/2026-08-31T14:37:53+00:00https://decoytx.com/decoy-therapeutics-stockholders-elect-patricia-gauthier-to-board-of-directors/2026-08-31T14:36:07+00:00https://decoytx.com/decoy-therapeutics-inc-announces-up-to-21-million-private-placement-financing/2026-06-26T12:00:00+00:00https://decoytx.com/june-2026-corporate-investor-presentation-available/2026-06-22T12:00:00+00:00https://decoytx.com/decoy-therapeutics-ceo-to-participate-in-hvivo-capital-markets-day-in-london/2026-06-08T12:00:00+00:00https://decoytx.com/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors/2026-06-03T12:00:00+00:00https://decoytx.com/decoy-therapeutics-partners-with-hvivo-to-advance-lead-d-mav-candidate-into-the-clinic/2026-06-01T12:00:00+00:00https://decoytx.com/decoy-therapeutics-names-brad-pentelute-mit-professor-of-chemistry-as-chair-of-scientific-advisory-board/2026-05-26T12:00:00+00:00https://decoytx.com/google-cloud-features-decoy-therapeutics-scaling-ai-driven-drug-discovery-for-global-impact/2026-05-15T12:00:00+00:00https://decoytx.com/decoy-therapeutics-to-present-at-two-peptide-therapeutics-conferences-in-boston/2026-04-27T12:00:00+00:00https://decoytx.com/decoy-therapeutics-builds-momentum-with-accelerating-execution-entering-a-highly-catalytic-phase-with-a-clearly-defined-path-to-clinical-development-of-its-antiviral-pipeline/2026-04-09T12:00:00+00:00https://decoytx.com/decoy-therapeutics-to-participate-in-virtual-investor-closing-bell-event-highlighting-business-outlook-for-2026/2026-04-06T12:00:00+00:00https://decoytx.com/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement/2026-04-02T12:00:00+00:00https://decoytx.com/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform/2026-03-11T12:00:00+00:00https://decoytx.com/decoy-therapeutics-announces-1-for-12-reverse-stock-split/2026-03-05T12:00:00+00:00https://decoytx.com/decoy-therapeutics-inc-has-been-selected-as-one-of-the-esteemed-hello-tomorrow-deep-tech-pioneers/2026-02-17T12:00:00+00:00https://decoytx.com/decoy-therapeutics-joins-webull-corporate-connect-service-platform/2026-02-11T12:00:00+00:00https://decoytx.com/decoy-therapeutics-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial/2026-02-05T12:00:00+00:00https://decoytx.com/decoy-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recently-announced-global-access-commitment-agreement/2026-02-04T12:00:00+00:00https://decoytx.com/decoy-therapeutics-reaches-global-access-commitment-agreement-to-focus-on-development-of-a-globally-accessible-scalable-peptide-conjugate-manufacturing-platform/2026-01-13T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-changes-corporate-name-to-decoy-therapeutics-and-nasdaq-ticker-symbol-to-dcoy-reflecting-focus-on-next-generation-peptide-conjugate-therapeutics/2026-01-07T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-meeting/2025-12-19T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform/2025-12-18T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-to-collaborate-with-texas-biomedical-research-institute-on-avian-flu-study/2025-12-01T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-cites-errors-on-sp-capiq-platform-following-merger-with-decoy-therapeutics-affirms-its-shares-continue-to-trade-on-the-nasdaq-stock-market-under-the-symbol-slrx/2025-11-19T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-and-decoy-therapeutics-complete-merger/2025-11-13T12:00:00+00:00https://decoytx.com/decoy-tx-receives-honorable-mention-top-10-for-nebius-ai-discovery-award-drug-discovery/2025-06-05T12:00:00+00:00https://decoytx.com/decoy-therapeutics-is-selected-as-semifinalist-of-the-nebius-ai-discovery-award-for-drug-discovery/2025-05-15T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-merger-partner-decoy-therapeutics-appoints-renowned-mit-professor-robert-s-langer-to-its-scientific-advisory-board/2025-04-16T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-merger-partner-decoy-therapeutics-announces-its-novel-inhibitors-show-promising-in-silico-activity-against-measles-and-related-viruses/2025-03-26T12:00:00+00:00https://decoytx.com/salarius-pharmaceuticals-and-decoy-therapeutics-announce-definitive-merger-agreement/2025-01-13T12:00:00+00:00https://decoytx.com/ceo-rick-pierce-receives-jlabs-community-member-of-the-year-award/2024-10-23T12:00:00+00:00https://decoytx.com/decoy-joins-github-for-startups-program-providing-a-suite-of-software-resources-for-their-developers-on-github/2024-07-19T12:00:00+00:00https://decoytx.com/decoy-accepted-into-nvidia-inception-program-to-build-their-ai-drug-discovery-platform-with-nvidia-gpus/2024-06-26T12:00:00+00:00https://decoytx.com/johnson-johnson-innovation-and-the-biomedical-advanced-research-and-development-authority-barda-name-awardees-in-the-blue-knight-resident-quickfire-challenge-partnering-for-preparedness/2024-06-02T12:00:00+00:00https://decoytx.com/decoy-selected-as-a-top-innovator-of-venture-summit-west-2024/2024-04-09T12:00:00+00:00https://decoytx.com/gates-notes-5-of-the-coolest-innovations-i-saw-in-senegal/2023-11-02T12:00:00+00:00https://decoytx.com/johnson-johnson-innovation-and-the-biomedical-advanced-research-and-development-authority-barda-names-awardees-in-the-blue-knight-quickfire-challenge-accelerating-project-nextgen/2023-08-24T12:00:00+00:00https://decoytx.com/decoy-joins-jetbrains-for-startups-program-offering-free-software-resources-for-their-developers/2023-08-18T12:00:00+00:00https://decoytx.com/decoys-ceo-rick-pierce-interviewed-by-stex25/2023-08-17T12:00:00+00:00https://decoytx.com/mit-startup-exchange-antiviral-drugs-offer-quick-defense-against-pandemics/2023-08-17T12:00:00+00:00https://decoytx.com/decoy-joins-google-for-startups-cloud-program-gaining-350000-usd-compute-credits-over-2-years-to-help-build-their-ai-drug-discovery-platform/2023-07-28T12:00:00+00:00https://decoytx.com/awardees-of-the-blue-knight-resident-quickfire-challenge-strive-toward-inflection-points/2023-04-03T12:00:00+00:00https://decoytx.com/mit-startup-exchange-decoy-joins-stex25-to-further-their-broad-acting-antivirals-program/2023-01-20T12:00:00+00:00https://decoytx.com/blue-knight-symposium-the-power-of-partnering-to-accelerate-preparedness/2022-06-09T12:00:00+00:00https://decoytx.com/decoy-receives-gates-foundation-grant-to-develop-a-rapid-response-technology-platform-against-emerging-pathogens/2021-09-01T12:00:00+00:00https://decoytx.com/decoy-enters-creative-destruction-lab-program-to-accelerate-their-peptide-conjugate-therapies/2021-01-01T12:00:00+00:00